Zhang Haowei, Gupta Ranju, Wang Jen C, Lipton Jeffrey F, Huang Yi-Wu
Division of Hematology/Oncology, Department of Medicine, Maimonides Medical Center Brooklyn, NY 11219, USA.
J Natl Med Assoc. 2007 Oct;99(10):1190-2.
Subcutaneous panniculitis-like T-cell lymphoma (SPTL) is a very rare postthymic T-cell non-Hodgkin's lymphoma with poor prognosis. There is not a standard treatment for this disease. Here we describe the first case of SPTL with unusual periorbital involvement, pancytopenia, hepatic dysfunction and coagulopathy, which was successfully treated with a chemotherapy regimen of cyclophosphamide, hydroxydaunomycin (doxorubicin), Oncovin (vincristine) and prednisone (CHOP). Our case demonstrates that although the natural history of SPTL is aggressive, patients may respond effectively to combination chemotherapy. Early recognition of the classic subcutaneous lesions and its associated systemic signs, such as unusual periorbital involvement, liver dysfunction and hemophagocytic syndrome, is very important in managing this aggressive lymphoma. Immunohistochemical and genetic studies are helpful in confirming the diagnosis. Early initiation of aggressive chemotherapy is recommended for better clinical outcome.
皮下脂膜炎样T细胞淋巴瘤(SPTL)是一种非常罕见的胸腺后T细胞非霍奇金淋巴瘤,预后较差。目前尚无针对该疾病的标准治疗方法。在此,我们报告首例伴有不寻常眶周受累、全血细胞减少、肝功能障碍和凝血病的SPTL病例,该病例通过环磷酰胺、羟基柔红霉素(阿霉素)、长春新碱和泼尼松(CHOP)化疗方案成功治愈。我们的病例表明,尽管SPTL的自然病程具有侵袭性,但患者可能对联合化疗有效反应。早期识别典型的皮下病变及其相关的全身症状,如不寻常的眶周受累、肝功能障碍和噬血细胞综合征,对于管理这种侵袭性淋巴瘤非常重要。免疫组织化学和基因研究有助于确诊。建议早期开始积极化疗以获得更好的临床结果。